Most studies investigating the clinical implications of FGF23 have focused on cardiovascular and all-cause mortality because of its pathophysiologic role in dysregulated mineral bone metabolism associated with cardiovascular damage and CKD progression23. The gene discussed is FGF23; the disease is chronic kidney disease.